HEALTHCARE SECTOR
![Pharma & healthcare mutual funds top return chart in August, offer 5% return](https://img.etimg.com/thumb/msid-112887828,width-100,height-75,resizemode-4/mf/analysis/pharma-healthcare-mutual-funds-top-return-chart-in-august-offer-5-return.jpg)
Pharma & healthcare mutual funds top return chart in August, offer 5% return
Mutual funds focused on pharma and healthcare sectors outperformed in August, delivering an average return of 4.75%. The WOC Pharma and Healthcare Fund led the category. Experts suggest investing via SIP mode with a 25% allocation to maintain a balanced portfolio. Positive outlook remains for the sector.
![Buy Fortis Healthcare, target price Rs 646: HDFC Securities](https://img.etimg.com/thumb/msid-112823408,width-100,height-75,resizemode-4/markets/stocks/recos/buy-fortis-healthcare-target-price-rs-646-hdfc-securities.jpg)
Buy Fortis Healthcare, target price Rs 646: HDFC Securities
Fortis Healthcare Ltd., incorporated in the year 1996, is a Mid Cap company (having a market cap of Rs 41016.88 Crore) operating in Hospitals & Allied Services sector.
![Long term Alpha generators: 8 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 27%](https://img.etimg.com/thumb/msid-112707891,width-100,height-75,resizemode-4/markets/stocks/news/long-term-alpha-generators-8-mid-and-small-cap-stocks-from-pharma-and-healthcare-sector-with-an-upside-potential-of-up-to-27.jpg)
Long term Alpha generators: 8 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 27%
After a long period of time, recently an Indian pharma company announced its intention to takeover a reasonably sized European company. This is more than just a single development, it is reflecting a change in underlying operating matrix of the pharma industry which for the last many years has been going through a period of readjustment and is now coming out of it. Not many may know that an Indian hospital chain operates a hospital in Cayman Island. The Indian healthcare and pharma sector are two spaces which probably will grow at a much faster rate than other sectors. There are both macro and micro factors which will lead to higher growth. It is faster growth which leads to generation of alpha, which ideally is what investors are seeking when taking risk in equities
![B'desh upheaval takes a toll on medical tourism in India](https://img.etimg.com/thumb/msid-112720242,width-100,height-75,resizemode-4/industry/healthcare/biotech/healthcare/bdesh-upheaval-takes-a-toll-on-medical-tourism-in-india.jpg)
B'desh upheaval takes a toll on medical tourism in India
The number of Bangladeshi patients visiting India for medical treatment has plummeted by up to 50% due to political unrest in Bangladesh. This downturn has impacted revenues for Indian hospitals. Pharma exports to Bangladesh are also at risk, as the country sources 30% of its pharmaceutical ingredients and raw materials from India, potentially affecting medication availability.
![Go for high-quality and high-growth segments of the market; look in these 4 sectors: Vinay Paharia](https://img.etimg.com/thumb/msid-112628708,width-100,height-75,resizemode-4/markets/expert-view/go-for-high-quality-and-high-growth-segments-of-the-market-look-in-these-4-sectors-vinay-paharia.jpg)
Go for high-quality and high-growth segments of the market; look in these 4 sectors: Vinay Paharia
Vinay Paharia, CIO of PGIM India Mutual Fund, identified overvalued conditions in smallcap and midcap segments but saw opportunities in high-quality, high-growth sectors such as IT, consumer discretionary, specialty chemicals, and healthcare. He highlighted the influence of potential rate cuts and capital flows driven by Bank of Japan's recent rate hikes on the market.
- Go To Page 1
Wear and tear: India's smartwatch market struggles amid fading interest
Not long ago, smartwatches and fitness trackers were a must-have in one’s digital wardrobe. But these devices are now falling out of favour among India’s youth. This unexpected shift, which has left a pile of inventory, offers a cautionary tale to brands. Tracking steps or sleep, switching watch faces and measuring heart rates are no longer exciting to Indian users.
As the Indian economy grows, a new definition of defensive stocks is required? 8 stocks from 2 sectors with upside potential up to 31%
On two significant days, first the election results on June 4th and second, last Monday, when there was a sharp sell off in global markets, on both the days, while Nifty and broader market was under severe pressure, it was FMCG stocks, which were able register gains. Explanation was the same old, that money is moving to defensive stocks. While moving to defensive stocks trade which has been taking place for some time. But there is a fundamental question. Given the fact that the Indian economy has changed and new sectors have emerged, whose growth is better and also stable, should FMCG stocks be considered defensive stocks ? The reason why it is important to understand this is the fact that over the next few quarters volatility might be high and there will be phases where this defensive stock trade might come and one should be prepared for it. Also their numbers are clearly indicating that time to make a shift has come.
Bajaj could make a difference in healthcare space
The Bajaj group's move into the hospital industry promises to influence the Indian healthcare sector. Private hospitals have shown growth and investor interest has risen post-pandemic. Bajaj plans to establish hospitals in metropolitan areas but will face significant hurdles such as high costs and a lack of medical professionals.
Hamara Hospital! Bajaj plans a healthcare ride
The Bajaj Group, worth ₹1.46 lakh crore, initiated steps to venture into the healthcare industry by setting up hospitals in metros. Overseen by Nirav Bajaj, the project will be housed in a new company, with phased investments based on milestones. This marks the group's first major diversification since Rahul Bajaj's death in 2022.
Clix Capital raises Rs 220 crore equity from existing investors including Apollo Global
The company plans to utilise these funds to strengthen its lending capabilities across the MSME, Education, and Healthcare Equipment sectors, enhance its credit profile & significantly invest in new-age AI & ML technologies. “Our investment in Clix Capital has seen significant value creation and we are delighted to have participated in this equity round. We see ample headroom for growth in Clix Capital’s journey as it expands its footprint in India’s growing MSME sector,” said Utsav Baijal, Partner and Head of India Private Equity, Apollo Global Management.
Unaprime buys Tata Healthcare's 43.5% in Lokmanya Hospitals
Lokmanya Hospitals has five hospitals located in Pune, Pimpri-Chinchwad and Kolhapur. The hospitals have an existing capacity of 300 beds and plan to expand to 500 beds.
Equity mutual funds offer up to 11% return in July. Have you invested in any?
Equity mutual funds saw impressive returns in July, with the Quant PSU Fund yielding 11.19% and the HDFC Technology Fund at 9.91%. Pharma and healthcare funds also performed well, with LIC MF Healthcare and Aditya Birla SL Pharma & Healthcare funds both returning around 9.7%. Overall, 566 out of 615 equity funds posted positive returns.
Stock Radar: Inverse Head & Shoulder pattern seen in Dr Lal PathLabs; time to buy?
Dr Lal PathLabs Ltd experienced a breakout from an inverse Head & Shoulder pattern, indicating a potential trend reversal. Experts recommend short-to-medium term traders to buy on dips, targeting above Rs 3,700. The stock has rebounded multiple times, most recently climbing above Rs 3,000 in July 2024, suggesting stronger support and potential upward momentum.
How equity mutual funds have performed after the Budget?
LIC MF Healthcare Fund, a healthcare sector based mutual fund, offered 4.71% return in the last week. Old Bridge Focused Equity Fund delivered 4.55% return in the said period. The next four funds in the list were from the pharma and healthcare sector.
Budget 2024: Cancer patients get relief but senior citizens missed the attention
The Union Budget 2024, while significantly increasing health sector funding to ₹90,959 crore, failed to address the BJP’s poll promise of including senior citizens above 70 in Ayushman Bharat-PMJAY. The budget features customs duty exemptions for three cancer drugs and changes to basic customs duty for X-ray equipment. Reactions from healthcare leaders underscore the budget's focus on improving accessibility and infrastructure. However, the omission of the senior citizens' health cover highlights a key unfulfilled promise, leaving a gap in comprehensive healthcare improvements.
Next leg of pharma sector growth necessitates skill advancement, innovation: Eco Survey
Economic Survey 2024: The domestic pharmaceutical industry in India needs skill advancement, innovation, and a robust supply chain to meet the expected segment size of USD 130 billion by 2030, according to the Economic Survey 2023-24 tabled in Parliament on Monday. Currently, the Indian pharmaceutical market is valued at around USD 50 billion, making it the world's third-largest by volume.
Budget 2024: Healthcare sector experts urge govt to boost spending, infrastructure and innovation
Experts in the healthcare sector are advocating for increased government spending, improved infrastructure, and enhanced innovation to strengthen India's healthcare system before the budget. They stress the importance of addressing health threats, achieving universal coverage, and professionalizing public health institutes. Recommendations include restructuring schemes, boosting domestic manufacturing, and increasing healthcare spending to 2.5% of GDP to enhance accessibility and affordability.
Union Budget 2024 should address these critical government & public sector challenges, experts say
BUDGET 2024 EXPECTATIONS: As India awaits its budget announcement, expectations are high, especially in the Government & Public Services (G&PS) sector. Facing outdated infrastructure, bureaucratic inefficiencies, and slow digital adoption, the upcoming budget offers a crucial chance to address these challenges and enhance service delivery, particularly in healthcare, education, and transportation.
Budget 2024: Will Sitharaman give a higher dose of allocation for healthcare this time around?
Budget Expectations 2024: India, under PM Narendra Modi’s leadership, has consistently increased healthcare allocation and spending. This trend continued with the Interim Budget for 2024-25, which holds particular importance as India nears the 2025 goal set by the National Health Policy (NHP) 2017 to raise health expenditure to 2.5% of GDP.
Alpha generators in the long term: 9 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 29%
While some make it to the headlines, some don't. Two sectors, healthcare and pharma have been witnessing more mergers and acquisitions than any other sector. There is a logical reason why private equity money is flowing in these sectors. Probably these two sectors are the ones with maximum potential to grow over the next decade or so. In the case of pharma, facts are well known, right from skilled manpower to lower manufacturing costs. In the case of healthcare, there are two things: first, medical tourism, second, soft exports of medical services. Not many may know, some of the best known doctors from India fly to CIS and other countries, where the healthcare companies have their OPD. Either the patient is treated there, if possible or else he is referred to India for treatment. While it might sound impossible, given the broken healthcare system which even some of the best developed countries have, in future, Indian healthcare companies taking over global hospitals may also become a reality.
Budget 2024: Is a Rs 10 lakh insurance the vitamin India's healthcare system needs?
The Centre is considering doubling the beneficiary base of the Ayushman Bharat health insurance scheme over the next three years, starting with those aged above 70, alongside raising annual coverage to Rs 10 lakh. These proposals are anticipated in the upcoming Union Budget. The interim Budget increased Ayushman Bharat's allocation to Rs 7,200 crore for secondary and tertiary care, with Rs 646 crore for health infrastructure.
Inclusive healthcare: H.E. Dr. Noura Khamis Al Ghaithi on Abu Dhabi’s vision beyond borders
In conversation with H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, who outlines the vision of the Abu Dhabi Global Healthcare Week (ADGHW) positioned to serve as an annual platform for inclusive knowledge-sharing and crafting collaborative strategies aimed at delivering positive patient outcomes.
KKR set to acquire Kerala's Baby Memorial Hospitals, make a comeback in hospital segment
KKR & Co plans to acquire a 70% stake in Kerala's Baby Memorial Hospital (BMH) for $300 million, marking its return to the Indian hospital sector. BMH, with 500 beds and expansion plans, is among Kerala’s largest hospitals. This move aligns with KKR’s strategy of expanding healthcare assets in India.
India's healthcare in critical condition: 4 out of 5 public health centers below par, reveals new Govt report
A recent Indian government self-assessment reveals that most public health facilities, including district hospitals and primary centers, fall short of essential standards. Only 20% meet benchmarks for infrastructure and resources, with 42% scoring below 50%. Initiatives aim to bring 70,000 facilities to standard within 100 days, backed by inspections and funding under the National Health Mission. This highlights urgent reforms needed to enhance healthcare nationwide, promising better services and equity in healthcare delivery.
Heatwaves: A reminder to focus on health as part of climate action
Heatwaves are affecting a huge proportion of India’s population with health problems, including heatstroke, dehydration and worsened chronic health conditions. With over 25,000 cases of heat stroke being reported since March, hospitals have witnessed a spike in heat-related illness cases, stretching already strained public health systems.
Tata Capital Healthcare Fund invests $20 million in Orbicular Pharmaceutical Technologies
The specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications. “Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets," said Visalakshi Chandramouli, managing partner, Tata Capital Healthcare Fund.
KKR invests in Healthcare Revenue Solutions provider Infinx
KKR acquires a significant minority stake in Infinx Services, a leading healthcare revenue cycle solutions provider. With Norwest Venture Partners also participating, the investment aims to accelerate Infinx's growth in the US healthcare market, leveraging KKR's expertise. Infinx's innovative platform serves over 400 healthcare providers, tapping into a $4.3 trillion market.
Load More